First Patients Dosed in Annovis Bio’s ANVS401 Trial, Delayed Due to COVID-19

First Patients Dosed in Annovis Bio’s ANVS401 Trial, Delayed Due to COVID-19
The first three patients have been dosed in a Phase 2a clinical trial investigating Annovis Bio's lead compound ANVS401 as a treatment for people with early Alzheimer's and Parkinson's diseases, the company said. The trial (NCT04524351) will recruit up to 68 participants at 15 sites scattered across the U.S. Thus far, only the sites in Florida and Utah are open for enrollment; more information can be found here. The remaining sites are in high COVID-19 areas and will open when the disease is less rampant.

“While COVID-19 has previously delayed trials for most biopharma companies, including the start of this trial, having a diverse mix of study sites should afford us the opportunity to maintain recruitment and treatment schedules moving forward,” Maria Maccecchini, PhD, CEO of Annovis Bio, said in a press release.

Diseases like Alzheimer's and Parkinson's are characterized by the buildup of toxic protein aggregates, or clumps, that interfere with normal neuronal processes, including nerve cell communication, protein transport, and brain inflammation. This eve

Subscribe or to access all post and page content.